Kornimate/medical-research-clean huggingface dataset:
deficit fields for stroke recovery

Conditions: Stroke

Summary: this study investigates the potential of customized robotic and visual feedback interaction to improve recovery of movements in stroke survivors. while therapists widely recognize that customization is critical to recovery, little is understood about how take advantage of statistical analysis tools to aid in the process of designing individualized training. our approach first creates a model of a person's own unique movement deficits, and then creates a practice environment to correct these problems. experiments will determine how the deficit-field approach can improve (1) reaching accuracy, (2) range of motion, and (3) activities of daily living. the findings will not only shed light on how to improve therapy for stroke survivors, it will test hypotheses about fundamental processes of practice and learning. this study will help us move closer to our long-term goal of clinically effective treatments using interactive devices.


Eligibility criteria:
inclusion criteria: stroke survivors: * adult (age \>18) * chronic stage stroke recovery (8+ months post) * available medical records and radiographic information about lesion locations * strokes caused by an ischemic infarct in the middle cerebral artery * primary motor cortex involvement * a fugl-meyer score (between 15-50) to evaluate arm motor impairment level healthy control participants: * adult (age \>18) * healthy individuals with no history of stroke or neural injury exclusion criteria: * bilateral paresis; * severe sensory deficits in the limb * severe spasticity (modified ashworth of 4) preventing movement * aphasia, cognitive impairment or affective dysfunction that would influence the ability to perform the experiment * inability to provide an informed consent * severe current medical problems * diffuse/multiple lesion sites or multiple stroke events * hemispatial neglect or visual field cut that would prevent subjects from seeing the targets.

Keywords: stroke upper extremity motor exploration error augmentation robotic rehabilitation
ovarian reserve in diabetes mellitus

Conditions: Type1 Diabetes Mellitus

Summary: type 1 diabetes mellitus is a common autoimmune disease. it affects women of all ages including reproductive years. hyperglycemic condition in diabetes can cause organ damage. this study aims to measure serum hormones including fsh, lh, e2, amh, ovarian volume and antral follicle count (indicators of ovarian reserve) in women with and without type 1 diabetes mellitus.

type 1 diabetes mellitus is a common autoimmune disease. it affects women of all ages including reproductive years. it is showed that hyperglycemic state in diabetes results in organ damage like kidneys and eyes. ovarian reserve is important for the reproductive period. the measurements of serum hormones including follicle stimulating hormone (fsh), luteinizing hormone (lh), estradiol (e2) and anti-mullerian hormone (amh) will give us an idea about the ovarian reserve. the investigators aim is to measure ovarian reserve parameters in patients diagnosed with type 1 diabetes mellitus and to compare them to healthy controls. serum fsh, lh, e2 and amh will be measured on the 3rd day of the cycle. antral follicle count and ovarian volume measurement will be done with ultrasonography. ovarian reserve markers will be compared between the groups.

Eligibility criteria:
inclusion criteria: * reproductive age group women: 18-40 years * women diagnosed with type 1 diabetes (case group) * women without type 1 diabetes (control group) exclusion criteria: * women with pcos (polycystic ovary syndrome) * history of ovarian surgery * body mass index (bmi) over 30
assessing force feedback with the softhand pro

Conditions: Amputation, Traumatic; Limb Defect

Summary: the trial is designed to test the effectiveness of a force-feedback cuff in combination with a myoelectric prosthesis in conveying information on grasp strength to the user, as well as the user's preference regarding the feature.

the human sensorimotor control system uses both feedforward planning and sensory feedback information, in order to actuate the musculoskeletal system and interact with the external environment, e.g. when modulating grip force for various object properties. as a result, lack of sensory input, as in the case of motor impairments or amputations, can dramatically affect activities of daily living (adls). the contribution of the proposed research will be to test the effectiveness of a novel, non-invasive prosthetic technology in delivering sensory information. the investigators' approach is "modality matching," in that it produces a sensation in the user similar to the type of information to be transmitted. specifically, the approach will combine the soft hand pro (shp), an anthropomorphic, myoelectrically controlled prosthetic hand, with an upper limb force feedback device (cuff) to provide patients with transradial amputations with grasp force (pressure) information.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years. 2. no prior experience with the cuff device. 3. history of elbow disarticulation, transradial, or transhumeral limb loss (non-control subjects only). exclusion criteria: 1. amputation for less than 6 months 2. clinical history of brachial plexopathy, cervical radiculopathy or polyneuropathy 3. orthopedic, joint degeneration (i.e., arthritis, verified by x-ray) affecting the hand or cervical spine that severely limit upper limb function 4. visual problems that would interfere with the grasp task 5. co-existing central nervous system disease with symptoms that limit upper extremity function (e.g., multiple sclerosis, motor neuron disease, myasthenia gravis, parkinson's disease, dystonia) revealed in medical history 6. significant rigidity as assessed through range of motion testing 7. active psychiatric illness 8. significant cognitive impairments (a score \< 24 on the mini-mental state examination) 9. use of medications that might affect sensory and/or motor functions 10. inability to effectively control myoelectrics for study purposes (control subjects only)

Keywords: cuff soft hand pro shp sh pro softhand
cyclosporine a in patients with small diameter abdominal aortic aneurysms

Conditions: Abdominal Aortic Aneurysm,; Small Abdominal Aortic Aneurysm

Summary: aneurysms of the aorta are dilatations of the main artery in the body that distributes blood to organs. aneurysms expose patients to aortic rupture. the risk of aortic rupture is high for large aneurysms, and low for small aneurysms. currently, if the diameter of a small aneurysm grows up to a level at risk for rupture, surgery is indicated to prevent rupture. a drug that would stop growth of small aneurysms would obviate aortic surgery, the current treatment to prevent aortic rupture in patients. the aca4 study aims at testing the possibility to stop growth of small aortic aneurysms in the abdomen with a drug, cyclosporine a. patients with small aneurysms will receive cyclosporine a orally, or a placebo (fake liquid), every day during a short period of time. efficacy of the drug will be evaluated by measuring the diameter of the aneurysm during 2 years after treatment cessation. drug safety analysis will evaluate the impact of the drug on renal function, blood pressure, and other parameters. in case of adverse event during the drug administration phase, dose of the drug or of the placebo will be decreased or administration stopped.

abdominal aortic aneurysms (aaas) expose patients to death caused by aortic rupture. although screening of aaas has been shown to decrease aaa-related mortality, translation into medical practice of screening is limited because there is no specific treatment to limit growth of aaas below diameter thresholds for open surgery or stent graft. we have developed different approaches aimed at inducing healing and thereby stabilizing formed aaas in animal models. we have identified tgf-beat1 as an inducer of experimental aaa healing. cyclosporine a is an inducer of tumor growth factor - beta1 (tgf-beta1) in experimental aaas and in human atherosclerotic aaas in vitro, causing overgrowth of inflamed tissues. since aaas are caused by aortic wall atrophy, we have hypothesised and confirmed in animals, that cyclosporine aaa, when administrated during a short period of time, durably stabilizes small aaa diameter in animals, while inducing aortic wall reconstruction and healing. the clinical trial aca4 is a multicentric randomized, placebo controlled, double blind trial that will enrol 360 patients with small aaas in france. two doses of cyclosporine a will be tested against a placebo (three arms). drug administration will be short, and aaa diameter evaluation will be performed for 2 years, by ct-scanner (main outcome) with no contrast, and duplex-scanner.

Eligibility criteria:
inclusion criteria: * male patients with asymptomatic aaa ≥ 30 mm, ≤ 49 mm * female patients with asymptomatic aaa ≥ 25 mm, ≤ 44 mm exclusion criteria: * common iliac aneurysm \> 25 mm * saccular aneurysm of the aorta * inflammatory aneurysm * no signature of informed consent * renal dysfunction * diabetes

Keywords: drug therapy prevention and control healing tissue regeneration therapy
infusion of dexmedetomidine versus lidocaine in management of acute postoperative pain after modified radical mastectomy

Conditions: Infusion; Dexmedetomidine; Lidocaine; Acute; Postoperative Pain; Modified Radical Mastectomy

Summary: this study aims to compare the effect of intraoperative intravenous infusion of dexmedetomidine and lidocaine in the management of acute postoperative pain after mastectomy.

postoperative pain control continues to remain suboptimal, despite multimodal analgesia regimes, minimally invasive surgical techniques, and enhanced recovery programs. acute postoperative pain hinders patients' functional recovery and represents one of the greatest predictive factors for transition to chronic postsurgical pain. among adjuvants, dexmedetomidine, a highly selective α2 adrenoreceptor agonist, and lidocaine, a well-established local anesthetic, seem promising for this purpose.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years. * american society of anesthesiology (asa) physical status ii. * body mass index (bmi) 18.5-35 kg/m2. * scheduled for modified radical mastectomy. exclusion criteria: * patient's refusal. * contraindication to the use of local anesthetics. * cardiovascular disease. * significant renal/hepatic impairment * insulin-dependent diabetes mellitus. * central nervous system or psychiatric disease. * use of opioids/steroids/clonidine/other α2 agonist/analgesics or any drugs acting on the central nervous system during the previous 2 weeks. * drug/alcohol abuse. * inability to comprehend the pain assessment scale.
the effect of infusion pressure on the outcomes of phacoemulsification surgery; the enhanse study

Conditions: Cataract

Summary: the effect of infusion pressure on the outcomes of phacoemulsification surgery.

the centurion phacoemulsification system with active sentry allows efficient cataract surgery with safe use of high vacuums, whilst allowing low and physiological infusion pressures, significantly lower than other surgical systems. there are reasons to expect that this will lead to patient benefit but it is uncertain if low infusion pressure during phacoemulsification will lead to improved outcomes. this is of particular interest in patients with vascular retinopathies such as diabetic retinopathy where the retinal vasculature is compromised, as well as glaucoma and other optic neuropathies where there is established nerve fibre layer loss. the investigator will carry out a feasibility study with a two surgeon rct of 70 patients with diabetic retinopathy and/or glaucoma undergoing phacoemulsification with randomisation of two different infusion pressures (low (30mmhg) versus the higher pressure (\~70mmhg) as currently used) using the active sentry system with assessment of a range of exploratory endpoints.

Eligibility criteria:
inclusion criteria: * patients with cataract undergoing routine phacoemulsification with either diabetic retinopathy or glaucoma of any degree exclusion criteria: * dense cataract precluding adequate retinal imaging * posterior polar cataract * subluxated cataract, * other vision affecting pathology, * severe glaucoma
recoverlink technology pilot for hf patients

Conditions: Heart Failure

Summary: the primary objective is to examine feasibility of incorporating recoverlink into the standard of care as a function of (i) user engagement, (ii) user satisfaction, and (iii) workflow efficiency. as secondary objectives, the investigators will collect preliminary data to examine the association between patient engagement with the recoverlink app and (i) changes in patient knowledge and behavior, and (ii) hospital readmission(s) at 30, 60, and 90-day time periods post-enrollment.


Eligibility criteria:
inclusion criteria: * heart failure (hf) patients with a rapid follow up appointment scheduled at the mount sinai hf clinic * english-speaking * with either access to (i) an ios smart device or (ii) wifi at-home exclusion criteria: patients meeting any of the following criteria: * a heart transplant * a mechanical circulatory support (mcs) device * an altered mental status * serious co-morbidities (as identified by mount sinai team) * cognitive impairments (as identified by mount sinai team) * inability to use technology (as identified by mount sinai team)

Keywords: heart failure mhealth
b7-h3 targeting car-t cells therapy for b7-h3 positive solid tumors

Conditions: Advanced Solid Tumor

Summary: this is a clinical study to evaluate the safety and efficacy of car-t cells in the treatment of patients with advanced solid tumors in china.

this is a single-center, single-arm, open-label study. this study is planned to enroll about 30 subjects with advanced solid tumors. autologous car-t cells were then infused intravenously into subjects, in a dose-escalating 3+3 design.

Eligibility criteria:
inclusion criteria: 1. aged 18-70 and of both sexes; 2. advanced solid tumor diagnosed by histology or pathology; 3. relapse after receiving chemotherapy or targeted drugs or other second-line therapy; 4. b7h3 antigen was positive in tumor tissues by immunohistochemistry, and the antigen expression rate was more than 15%. 5. patients had at least one evaluable tumor lesion according to recist 1.1 criteria that could be accurately measured at baseline; 6. the ecog score is 0-2, and the expected survival time is more than 12 weeks; 7. laboratory test results should at least meet the following requirements: left ventricular ejection fraction ≥40%; creatinine ≤200 umol/l; absolute neutrophil count (anc) ≥1.5×109/l; platelet (plt) ≥80×109/l; hemoglobin ≥80g/l; oxygen saturation of blood 91%; total bilirubin ≤2×uln; alt and ast 2.5 x uln or less; the criteria for abnormal alt and ast due to disease (e.g., liver metastases or bile duct obstruction) or gilbert syndrome can be relaxed to ≤5×uln. 8. having venous access for blood collection or single blood collection; 9. the patient voluntarily participated and signed the informed consent in person. exclusion criteria: 1. pregnant or lactating women; 2. chemotherapy or radiotherapy was used within 3 days before the blood collection period; 3. patients who have used systemic steroids within 5 days before blood collection period (except those who have recently or currently used inhaled steroids); 4. use drugs to stimulate bone marrow hematopoietic cell formation within 5 days before the blood collection period; 5. those who have used any gene or cell therapy products; 6. history of epilepsy or other central nervous system diseases; 7. active hepatitis b or c virus, defined as: hepatitis b surface antigen hbsag or hepatitis b core antibody hbcab positive subjects with peripheral blood hbv dna titer above the detection limit; hcv antibody positive for hepatitis c and hcv rna positive in peripheral blood; people infected with hiv and syphilis; 8. other tumors in the past 5 years; 9. patients with severe chest and ascites; 10. there was active or uncontrollable infection requiring systemic treatment within 14 days before enrollment; 11. other antineoplastic treatments (other than pretreatment and chemotherapy) were administered within 2 weeks before study initiation; 12. the investigator assessed that the patient was unable or unwilling to comply with the protocol.
a study of ly3437943 in participants with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the main purpose of this study is to evaluate the efficacy and safety of ly3437943 in participants with type 2 diabetes (t2d) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. this study will last about 43 weeks.


Eligibility criteria:
inclusion criteria: * have type 2 diabetes (t2d) * have an hba1c value at screening of ≥7.0% and ≤10.5% and treated with diet and exercise alone or with a stable dose of metformin (either immediate release or extended release, 1000 milligram (mg)/day and not more than the locally approved dose) for at least 3 months prior to screening. exclusion criteria: * have type 1 diabetes mellitus (t1dm) * have ketoacidosis * have retinopathy, maculopathy * have history of pancreatitis * have obesity induced by other endocrine disorders * have uncontrolled hypertension * have acute or chronic hepatitis * have chronic kidney disease * have an autoimmune abnormality for example, lupus or rheumatoid arthritis * have an active or untreated malignancy
nasogastric tube clamping trial vs. immediate removal

Conditions: Small Bowel Obstruction; Ileus

Summary: the primary objective is to assess the need of clamping nasogastric tubes (ng) before removal. outcomes of patients admitted requiring nasogastric tube decompression will be compared. patients with small bowel obstruction (sbo), post-operative ileus, and ileus on admission that require nasogastric tube placement will be included in the study. the patients will be divided into two groups when return of bowel function is suspected based on set criteria for automatic removal of nasogastric tube versus nasogastric tube clamp trial. specific outcomes will be occurrence of nasogastric tube replacement, number of emeses if any, failure of clamp trial, aspiration pneumonia, and any other unplanned outcome.

a high volume of patients are admitted to hospitals yearly for bowel obstruction/ileus complications. lifetime risk of small bowel obstruction varies from 0.1%-5% if patients have not undergone abdominal surgery, but increases to 30% if the patient underwent a prior abdominal surgery. ileus is also a common complication in the short term post-operative period. both of these conditions are initially treated with nasogastric tube decompression if the patient is having emesis. the investigators were unable to find any literature that shows a concrete volume of nasogastric tube output that was deemed the maximum for safe removal. signs of return of bowel function can indicate it is safe to remove the nasogastric tube. these include flatus, bowel movements, decrease in nasogastric tube output amount, change of nasogastric tube output color from bilious (green) to more gastric (yellow) or salivary (clear/foamy) quality. some physicians prefer to perform a clamp trial before removal of the nasogastric tube. the duration of the trial and cutoff amount of residual drainage varies among physicians. regardless of the duration, the nasogastric tube is essentially stenting open the lower esophageal sphincter while it is left in place and not connected to suction. this, theoretically, places the patient at risk for aspiration and subsequent pneumonia. information in the literature appears divided in regard to aspiration risk. this study hopefully will support the statement that it is safe to remove the nasogastric tube with signs of bowel function, without the need for clamp trials and thus avoiding any possible adverse outcomes associated with the trial. the investigators also anticipate that this study will provide objective guidelines on which patients will continue to improve after nasogastric tube removal.

Eligibility criteria:
inclusion criteria: * males or females 18 years or older * admitted under any of the teaching surgical services for small bowel obstruction or ileus, or develops post-operative ileus * patient agreeable to participation in the study exclusion criteria: * under the age of 18 * patient self-removes the ng requiring replacement will be removed from study
comparison of two different type robot assisted gait training in rehabilitation of stroke

Conditions: Stroke

Summary: investigators aimed to compare the results of rehabilitation with an exoskeleton device(robogait) and with an end-effector device(lokohelp)

there are different types of devices in robotic rehabilitation which has been used in recent years for stroke. investigators aimed to compare the results of rehabilitation with an exoskeleton device(robogait) and with an end-effector device(lokohelp) in robot-assisted gait training of stroke rehabilitation

Eligibility criteria:
inclusion criteria: * rehabilitation need for stroke * patients under fac stage 4 * no contraindications for robotic rehabilitation * subacute stroke exclusion criteria: * the robot-orthosis does not fit the patient's body * inadequate body weight (obesity) * severe contractures * bone instability (nonstable spinal cord fracture and severe osteoporosis) * circulation problems * cardiac problems * open wounds on the lower extremities or in the body where they will come into contact with the orthosis * uncoordinated, psychotic or aggressive patients * serious cognitive disorders * patients with long-term infusion therapy * hip, knee, ankle arthrodesis * epilepsy * patients with disproportionate limb or vertebrae, such as bone cartilage dysplasia * those with severe vascular problems of the lower extremity * conditions requiring rest or immobilization, such as osteomyelitis and other inflammatory/infectious diseases * severe respiratory diseases
comparison of sp tfl and ho:yag for rirs using 145 µm and 200 µm fibers

Conditions: Kidney Stone; Nephrolithiasis; Urolithiasis

Summary: the authors hypothesize that the rirs using 150-microm tm-fiber laser is superior than fiber with larger diameters, as 200-microm tm-fiber laser or 200-microm holmium fiber laser, in such points as follows: * decreasing surgery time and laser-on time due to possibility of 4.3 fold ablation efficacy increase, which has been shown by andreeva et al.; * increasing the flexible ureteroscope tip deflection lower pole stones availability; * decreased risk of complications and a better irrigation and visualization due to better irrigation with smaller fiber; * increasing of lithotripsy efficacy and laser beam density by lowering of beam focal spot due to using of lesser fiber diameter

rirs will be performed with sp tfl or ho:yag (100 w). the procedure is performed under general anesthesia with the patient in the dorsal lithotomy position. the bladder is entered either with a cystoscope or a semi-rigid ureterorenoscope. guidewires (0.035") will be used to facilitate access (under fluoroscopic guidance). after access sheath (12/14) will be placed up to the kidney pelvis. through the access sheath ureteroscope will be introduced. for nephrolithotripsy 145 mcm and 200 mcm fibers will be used. large fragments could be extracted with nitinol basket. after the surgery ureteral stent (7 fr.) will be placed inside the ureter for 10 to 14 days. a 10 fr urethral catheter can be placed in the bladder for the drainage of the bladder during the operation.

Eligibility criteria:
inclusion criteria: * males and females \> 18 y.o.; * radiologically confirmed (ct) kidney stone; * stone size from 10 to 20 mm. exclusion criteria: • multiple (more than 3) kidney stones \> 5 mm

Keywords: rirs holmium laser superpulse thulium laser kidney stone disease